Results 111 to 120 of about 50,941 (289)

Cognitive and neurodevelopmental disorders in spinal muscular atrophy type I at the time of disease‐modifying therapies

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract After treatment with new disease‐modifying therapies, cognitive and neurodevelopmental aspects have been observed in individuals with spinal muscular atrophy (SMA). Emerging evidence suggests that children with SMA type 1 may experience cognitive, language, and behavioural delays, with reported rates of neurodevelopmental difficulties ranging ...
Giorgia Coratti   +2 more
wiley   +1 more source

Global, regional and national burden of epilepsy in children and adolescents, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
Globally, in 2021, there were 18.15 million prevalent cases of epilepsy in children and adolescents (8.24 and 9.91 million of idiopathic and secondary epilepsy, respectively). Between 1990 and 2021, the prevalence rate of secondary epilepsy increased by 16.14%, with especially high increases attributable to neonatal encephalopathy, neonatal jaundice ...
Yun Seo Kim   +10 more
wiley   +1 more source

Congenital bilateral laryngeal paralysis in a neonatal foal—Expanding our understanding of neonatal airway dysfunction

open access: yesEquine Veterinary Education, EarlyView.
Summary The case report by De Maré et al. 2025 describes a rare but instructive case of bilateral laryngeal paralysis in a newborn Warmblood foal with suspected neonatal encephalopathy (NE). The foal presented with inspiratory stridor from birth and was successfully managed through supportive medical therapy and temporary nasotracheal intubation, with ...
M. Abraham
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Influences of perinatal asphyxia on respiratory distress syndrome

open access: bronze, 1988
John Johnson   +2 more
openalex   +1 more source

Home - About - Disclaimer - Privacy